Effect of cinacalcet on bone mineral density of the radius in hemodialysis patients with secondary hyperparathyroidism

Clinical Nephrology

Volumn 76, Issue 4, 2011, Pages 259-265

  Ishimura, E ^a   Okuno, S ^b   Tsuboniwa, N ^b   Ichii, M ^a   Yamakawa, K ^b   Yamakawa, T ^b   Shoji, S ^b   Nishizawa, Y ^a   Inaba, M ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Shirasagi Hospital   (Japan)

Author keywords

Bone mineral density; Cinacalcet; Dual X ray absorptiometry; Secondary hyperparathyroidism

Indexed keywords

CINACALCET;

ADULT; ARTICLE; BONE DENSITY; CANCELLOUS BONE; CORTICAL BONE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; RADIUS; SECONDARY HYPERPARATHYROIDISM;

ABSORPTIOMETRY, PHOTON; ANALYSIS OF VARIANCE; BONE DENSITY; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; RADIUS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 82155173197     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107052     Document Type: Article

References (36)

1. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Miner Electrolyte Metab. 1995; 21: 91-96.
2. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G; Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69: 1945-1953.
3. KDIGO. clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009; 76 (Suppl 113): S22-S49.
4. Foldes AJ, Arnon E, Popovtzer MM. Reduced speed of sound in tibial bone of haemodialysed patients: association with serum PTH level. Nephrol Dial Transplant. 1996; 11: 1318-1321.
5. Taal MW, Masud T, Green D, Cassidy MJ. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant. 1999; 14: 1922-1928.
6. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001; 12: 2131-2138.
7. Nakai S, Akiba T, Kazama J, Yokoyama K, Fukagawa M, Tominaga Y, Iseki K, Tsubakihara Y; Patient Registration Committee of the Japanese Society for Dialysis Therapy, Tokyo, Japan. Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial. 2008; 12: 49-54.
8. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN, Brown AJ. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest. 1996; 97: 2534-2540.
9. Thadhani R, Wolf M. Vitamin D in patients with kidney disease: cautiously optimistic. Adv Chronic Kidney Dis. 2007; 14: 22-26.
10. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, Martin D. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther. 2004; 308: 627-635.
11. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004; 350: 1516-1525.
12. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005; 16: 800-807.
13. Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM. Longterm treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005; 20: 2186-2193.
14. Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S; KRN1493 study group. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant. 2008; 23: 328-335.
15. Ichii M, Ishimura E, Okuno S, Chou H, Kato Y, Tsuboniwa N, Nagasue K, Maekawa K, Yamakawa T, Inaba M, Nishizawa Y. Decreases in parathyroid gland volume after cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism. Nephron Clin Pract. 2010; 115: c195-c202.
16. Malluche HH, Monier-Faugere MC, Wang G, Frazã O JM, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2008; 69: 269-278.
17. Shigematsu T, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S; KRN1493 Study Group. Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol. 2009; 29: 230-236.
18. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005; 68: 1793-1800.
19. Yano S, Sugimoto T, Tsukamoto T, Yamaguchi T, Hattori T, Sekita KI, Kaji H, Hattori S, Kobayashi A, Chihara K. Effect of parathyroidectomy on bone mineral density in hemodialysis patients with secondary hyperparathyroidism: possible usefulness of preoperative determination of parathyroid hormone level for prediction of bone regain. Horm Metab Res. 2003; 35: 259-264.
20. Abdelhadi M, Nordenström J. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab. 1998; 83: 3845-3851.
21. Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2005; 20: 1232-1237.
22. Baron-R. Anatomy and ultrastructure of bone. In: Fravus MJ (ed). Primer on the metabolic bone diseases and disorders of mineral metabolism. Lippincott Williams, Philadelphia, 1999. p. 3-10.
23. Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial. 2008; 12: 514-525.
24. Kohno K, Inaba M, Okuno S, Maeno Y, Maekawa K, Yamakawa T, Ishimura E, Nishizawa Y. Association of reduction in bone mineral density with mortality in male hemodialysis patients. Calcif Tissue Int. 2009; 84: 180-185.
25. Abugassa S, Nordenström J, Eriksson S, Möllerström G, Alveryd A. Skeletal remineralization after surgery for primary and secondary hyperparathyroidism. Surgery. 1990; 107: 128-133.
26. Christiansen P, Steiniche T, Brixen K, Hessov I, Melsen F, Heickendorff L, Mosekilde L. Primary hyperparathyroidism: effect of parathyroidectomy on regional bone mineral density in Danish patients: a three-year follow-up study. Bone. 1999; 25: 589-595.
27. Kaye M, Rosenthall L, Hill RO, Tabah RJ. Longterm outcome following total parathyroidectomy in patients with end-stage renal disease. Clin Nephrol. 1993; 39: 192-197.
28. Chou FF, Lee CH, Lee CT. Muscle force and bone mineral density after parathyroidectomy and subcutaneous autotransplantation for secondary hyperparathyroidism. World J Surg. 1999; 23: 452-456, discussion 456-457.
29. Dempster DW, Parisien M, Silverberg SJ, Liang XG, Schnitzer M, Shen V, Shane E, Kimmel DB, Recker R, Lindsay R, Bilezikian JP. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab. 1999; 84: 1562-1566.
30. Negri AL, Barone R, Lombas C, Bogado CE, Zanchetta JR. Evaluation of cortical bone by peripheral quantitative computed tomography in continuous ambulatory peritoneal dialysis patients. Hemodial Int. 2006; 10: 351-355.
31. Yajima A, Inaba M, Tominaga Y, Ito A. Minimodeling reduces the rate of cortical bone loss in patients with secondary hyperparathyroidism. Am J Kidney Dis. 2007; 49: 440-451.
32. Schober HC, Han ZH, Foldes AJ, Shih MS, Rao DS, Balena R, Parfitt AM. Mineralized bone loss at different sites in dialysis patients: implications for prevention. J Am Soc Nephrol. 1998; 9: 1225-1233.
33. Fontaine MA, Albert A, Dubois B, Saint-Remy A, Rorive G. Fracture and bone mineral density in hemodialysis patients. Clin Nephrol. 2000; 54: 218-226.
34. Yajima A, Inaba M, Ogawa Y, Tominaga Y, Tanizawa T, Inou T, Otsubo O. Significance of time-course changes of serum bone markers after parathyroidectomy in patients with uraemic hyperparathyroidism. Nephrol Dial Transplant. 2007; 22: 1645-1657.
35. Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, Sprague SM, Goldfarb S. Kdoqi us commentary on the 2009 kdigo clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-mineral and bone disorder (CKD-MBD). Am J Kidney Dis. 2010; 55: 773-799.
36. Jamal SA, Hayden JA, Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis. 2007; 49: 674-681.